Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model
- PMID: 17387150
- PMCID: PMC1891373
- DOI: 10.1128/AAC.00873-06
Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model
Abstract
Triple antifungal combinations are used against refractory invasive aspergillosis without an adequate understanding of their pharmacodynamic interactions. We initially studied the in vitro triple combination of voriconazole, amphotericin B, and caspofungin against Aspergillus fumigatus, A. flavus, and A. terreus by a spectrophotometric microdilution broth method after 48 h of incubation. We then analyzed these results with a recently described nonlinear mixture response surface E(max)-based model modified to assess pharmacodynamic interactions at various growth levels. The new model allows flexibility in all four parameters of the E(max) model and is able to describe complex pharmacodynamic interactions. Concentration-dependent pharmacodynamic interactions were found within the triple antifungal combination. At the 50% growth level, synergy (median interaction indices of 0.43 to 0.82) was observed at low concentrations of voriconazole (<0.03 mg/liter) and amphotericin B (</=0.20 mg/liter) and at intermediate concentrations of caspofungin (0.95 to 14.88 mg/liter), whereas antagonism (median interaction indices of 1.17 to 1.80) was found at higher concentrations of voriconazole and amphotericin B. Ternary plot and interaction surface analysis further revealed the complexity of these concentration-dependent interactions. With increasing concentrations of amphotericin B, the synergistic interactions of voriconazole-caspofungin double combination decreased while the antagonistic interactions increased. A similar effect was observed when voriconazole was added to the double combination of amphotericin B and caspofungin. In conclusion, the new nonlinear mixture-amount response surface modeling of the triple antifungal combination demonstrated a net antagonism or synergy against Aspergillus species depending upon drug concentrations and species.
Figures






Similar articles
-
Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species.J Antimicrob Chemother. 2006 Dec;58(6):1168-76. doi: 10.1093/jac/dkl392. Epub 2006 Oct 27. J Antimicrob Chemother. 2006. PMID: 17071635
-
Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions.Antimicrob Agents Chemother. 2013 Oct;57(10):4656-63. doi: 10.1128/AAC.00597-13. Epub 2013 Jul 15. Antimicrob Agents Chemother. 2013. PMID: 23856768 Free PMC article.
-
Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.Antimicrob Agents Chemother. 2005 Mar;49(3):1232-5. doi: 10.1128/AAC.49.3.1232-1235.2005. Antimicrob Agents Chemother. 2005. PMID: 15728937 Free PMC article.
-
In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.Rev Iberoam Micol. 2003 Dec;20(4):121-36. Rev Iberoam Micol. 2003. PMID: 15456349 Review.
-
Caspofungin: a major breakthrough in treatment of systemic fungal infections.J Assoc Physicians India. 2006 Dec;54:943-8. J Assoc Physicians India. 2006. PMID: 17334012 Review.
Cited by
-
Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.Antimicrob Agents Chemother. 2015 Jul;59(7):3973-83. doi: 10.1128/AAC.05035-14. Epub 2015 Apr 20. Antimicrob Agents Chemother. 2015. PMID: 25896699 Free PMC article.
-
Multicenter Collaborative Study of the Interaction of Antifungal Combinations against Candida Spp. by Loewe Additivity and Bliss Independence-Based Response Surface Analysis.J Fungi (Basel). 2022 Sep 16;8(9):967. doi: 10.3390/jof8090967. J Fungi (Basel). 2022. PMID: 36135692 Free PMC article.
-
Immunosuppressive Compounds Affect the Fungal Growth and Viability of Defined Aspergillus Species.Pathogens. 2019 Nov 29;8(4):273. doi: 10.3390/pathogens8040273. Pathogens. 2019. PMID: 31795350 Free PMC article.
-
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Infection. 2017 Dec;45(6):737-779. doi: 10.1007/s15010-017-1042-z. Epub 2017 Jul 12. Infection. 2017. PMID: 28702763 Free PMC article. Review.
-
Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum.PLoS Pathog. 2012 Jan;8(1):e1002487. doi: 10.1371/journal.ppat.1002487. Epub 2012 Jan 12. PLoS Pathog. 2012. PMID: 22253599 Free PMC article.
References
-
- Chandrasekar, P. H., J. L. Cutright, and E. K. Manavathu. 2004. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clin. Microbiol. Infect. 10:925-928. - PubMed
-
- Clemons, K. V., M. Espiritu, R. Parmar, and D. A. Stevens. 2005. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob. Agents Chemother. 49:4867-4875. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources